Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.

Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaaw3163. doi: 10.1126/scitranslmed.aaw3163.


Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus.

Schaeffer J, Reynard S, Carnec X, Pietrosemoli N, Dillies MA, Baize S.

Viruses. 2019 Mar 21;11(3). pii: E287. doi: 10.3390/v11030287.


Immune parameters and outcomes during Ebola virus disease.

Reynard S, Journeaux A, Gloaguen E, Schaeffer J, Varet H, Pietrosemoli N, Mateo M, Baillet N, Laouenan C, Raoul H, Mullaert J, Baize S.

JCI Insight. 2019 Jan 10;4(1). pii: 125106. doi: 10.1172/jci.insight.125106. [Epub ahead of print]


Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells.

Schaeffer J, Carnec X, Reynard S, Mateo M, Picard C, Pietrosemoli N, Dillies MA, Baize S.

PLoS Pathog. 2018 Nov 12;14(11):e1007430. doi: 10.1371/journal.ppat.1007430. eCollection 2018 Nov.


Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.

Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.


A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S.

J Virol. 2018 May 29;92(12). pii: e02230-17. doi: 10.1128/JVI.02230-17. Print 2018 Jun 15.


Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.

Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, Burlaud Gaillard J, Confort MP, Escudero-Perez B, Gruffat H, Hong SS, Moroso M, Reynard O, Reynard S, Decembre E, Ftaich N, Rossi A, Wu N, Arnaud F, Baize S, Dreux M, Gerlier D, Paranhos-Baccala G, Volchkov V, Roingeard P, Cimarelli A.

PLoS Pathog. 2017 Sep 28;13(9):e1006610. doi: 10.1371/journal.ppat.1006610. eCollection 2017 Sep.


Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea.

Vernet MA, Reynard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Rives M, Georges N, Garcia-Bonnet N, Sylla AI, Grovogui P, Kerherve JY, Savio C, Savio-Coste S, de Séverac ML, Zloczewski P, Linares S, Harouna S, Abdoul BM, Petitjean F, Samake N, Shepherd S, Kinda M, Koundouno FR, Joxe L, Mateo M, Lecine P, Page A, Tchamdja TM, Schoenhals M, Barbe S, Simon B, Tran-Minh T, Longuet C, L'Hériteau F, Baize S.

JCI Insight. 2017 Mar 23;2(6):e88864. doi: 10.1172/jci.insight.88864.


Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.

Reynard S, Russier M, Fizet A, Carnec X, Baize S.

J Virol. 2014 Dec;88(23):13923-7. doi: 10.1128/JVI.01923-14. Epub 2014 Sep 24.


The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses.

Russier M, Reynard S, Carnec X, Baize S.

J Virol. 2014 Dec;88(23):13811-20. doi: 10.1128/JVI.01908-14. Epub 2014 Sep 24.


Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever.

Pannetier D, Reynard S, Russier M, Carnec X, Baize S.

PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2637. doi: 10.1371/journal.pntd.0002637. eCollection 2014.


NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression.

Russier M, Reynard S, Tordo N, Baize S.

Eur J Immunol. 2012 Jul;42(7):1822-32. doi: 10.1002/eji.201142099.


Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Carnec X, Baize S, Reynard S, Diancourt L, Caro V, Tordo N, Bouloy M.

J Virol. 2011 Nov;85(22):12093-7. doi: 10.1128/JVI.00429-11. Epub 2011 Aug 31.


Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V, Baize S.

J Virol. 2011 Aug;85(16):8293-306. doi: 10.1128/JVI.02120-10. Epub 2011 Jun 1.


KAP1 controls endogenous retroviruses in embryonic stem cells.

Rowe HM, Jakobsson J, Mesnard D, Rougemont J, Reynard S, Aktas T, Maillard PV, Layard-Liesching H, Verp S, Marquis J, Spitz F, Constam DB, Trono D.

Nature. 2010 Jan 14;463(7278):237-40. doi: 10.1038/nature08674.


Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H.

J Virol. 2009 Jun;83(11):5890-903. doi: 10.1128/JVI.01948-08. Epub 2009 Mar 18.


Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.

Voelter V, Rufer N, Reynard S, Greub G, Brookes R, Guillaume P, Grosjean F, Fagerberg T, Michelin O, Rowland-Jones S, Pinilla C, Leyvraz S, Romero P, Appay V.

Int Immunol. 2008 Aug;20(8):1087-96. doi: 10.1093/intimm/dxn066. Epub 2008 Jun 23.


Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha.

Maillard PV, Reynard S, Serhan F, Turelli P, Trono D.

PLoS Pathog. 2007 Dec 28;3(12):e200. doi: 10.1371/journal.ppat.0030200.


West Nile virus in wild resident birds, Southern France, 2004.

Jourdain E, Schuffenecker I, Korimbocus J, Reynard S, Murri S, Kayser Y, Gauthier-Clerc M, Sabatier P, Zeller HG.

Vector Borne Zoonotic Dis. 2007 Fall;7(3):448-52.


Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.

J Immunother. 2007 Feb-Mar;30(2):240-50.


New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.

J Immunol. 2006 Aug 1;177(3):1670-8.


Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.

Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C, Romero P.

Eur J Immunol. 2006 Jul;36(7):1805-14.


Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.

Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S.

J Immunol Methods. 2006 Feb 20;309(1-2):192-9. Epub 2005 Dec 27.


Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.

Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, Guillaume P, Cerottini JC, Romero P, Leyvraz S.

Clin Exp Immunol. 2005 Nov;142(2):292-302.


TRAIL receptor-2 signals apoptosis through FADD and caspase-8.

Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J.

Nat Cell Biol. 2000 Apr;2(4):241-3. No abstract available.


Supplemental Content

Loading ...
Support Center